Impact of a moderate-intensity walking program on cardiometabolic risk markers in overweight to obese women: is there any influence of menopause?

Menopause. 2013 Feb;20(2):185-93. doi: 10.1097/gme.0b013e31826f7ebf.

Abstract

Objective: The aim of this study was to examine the effect of brisk walking on cardiometabolic risk profile and on the gene expression (ie, messenger RNA [mRNA] levels) of inflammatory and thrombotic markers in abdominal and femoral subcutaneous adipose tissues (SATs) among sedentary overweight to obese women with different menopause statuses.

Methods: Sixteen late premenopausal (mean [SD] age, 49 [3] y; mean [SD] body mass index, 31.9 [3.0] kg/m) and 14 early postmenopausal (53 [2] y; 30.8 [1.9] kg/m) women were involved in a 16-week walking program (three sessions of 45 min/wk at 60% of heart rate reserve). Glucose-insulin homeostasis, lipid-lipoprotein profile, and inflammatory (tumor necrosis factor-α, interleukin-6 [IL-6], and adiponectin) and thrombotic (plasminogen activator inhibitor-1) SAT mRNA and plasma levels were measured before and after the intervention.

Results: Glucose area under the curve was reduced in all participants (P = 0.03) after the walking program. Increases in plasma tumor necrosis factor-α were observed in both groups (P = 0.001), whereas increases in plasminogen activator inhibitor-1 levels were found in postmenopausal women only (P = 0.014). However, plasma IL-6 and adiponectin levels remained unchanged after the intervention (0.07 < P < 0.98). Although femoral SAT adiponectin mRNA levels decreased in postmenopausal women only (P = 0.008), abdominal SAT IL-6 mRNA levels were reduced in both groups (P = 0.01).

Conclusions: Taken together, our results show that, despite a reduced abdominal SAT IL-6 expression, brisk walking does not seem to exert a favorable impact on the cardiometabolic risk profile of overweight to obese women, irrespective of their menopause status.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adiponectin / genetics
  • Body Mass Index
  • Coronary Disease / etiology
  • Coronary Disease / prevention & control*
  • Exercise
  • Female
  • Humans
  • Interleukin-6 / genetics
  • Menopause / physiology*
  • Metabolic Syndrome / etiology
  • Metabolic Syndrome / prevention & control*
  • Middle Aged
  • Obesity / therapy*
  • Overweight / therapy*
  • Plasminogen Activator Inhibitor 1 / blood
  • Postmenopause / physiology
  • Premenopause / physiology
  • RNA, Messenger
  • Risk Factors
  • Subcutaneous Fat / chemistry
  • Tumor Necrosis Factor-alpha / blood
  • Walking*

Substances

  • Adiponectin
  • Interleukin-6
  • Plasminogen Activator Inhibitor 1
  • RNA, Messenger
  • Tumor Necrosis Factor-alpha